CTRI/2021/05/033759
Not yet recruiting
未知
Comparison of continuous infusion and intermittent bolus infusion for postoperative patient-controlled analgesia with erector spinae block catheter: a randomized, double- blind, controlled trial
AIIMS Patna0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Sponsor
- AIIMS Patna
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •ASA I/II female patients scheduled for unilateral MRM under general anaesthesia
Exclusion Criteria
- •Patients unable to cooperate or give consent
- •Known allergy to local anesthetic, non\-steroidal anti\-inflammatory drugs or opioids,
- •Infection at the injection site,
- •Coagulopathy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Treatment of Organophosphate poisoning with PralidoximeIRCT20180613040087N1Shiraz University of Medical Sciences80
Recruiting
Phase 3
A study to compare two different ways of giving fentanyl drugâ?? continuous infusion or intermittent doses for pain relief in newborn babiesCTRI/2014/11/005190Institutional Review Board98
Completed
Phase 2
Comparison of two different methods of drug administration in Adductor Canal Block after Knee arthroplasty.CTRI/2019/01/017279AIIMS Rishikesh80
Completed
Not Applicable
Comparison of continuous medication versus intermittent medication through regional anaesthetic technique in breast cancer patients undergoing surgeryHealth Condition 1: C508- Malignant neoplasm of overlappingsites of breastCTRI/2019/08/020751AIIMS50
Active, not recruiting
Phase 1
Continuous infusion versus intermittent administration of meropenem in critically ill patients. A multicenter randomized double blind trial.We are planning a large multicentre randomized controlled study to confirm the beneficial effect of continuous infusion of meropenem against bolus administration as indicated by a composite outcome of reducing death, and emergence of extensive or pan drug resistant pathogens in a population of severely ill patients.MedDRA version: 20.0Level: LLTClassification code 10062357Term: SIRSSystem Organ Class: 100000004867Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-002052-24-ITOSPEDALE SAN RAFFAELE600